Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States.

ABSTRACT:

Background

Population genomic screening for familial hypercholesterolemia (FH) in unselected individuals can prevent premature cardiovascular disease.

Objective

To estimate the clinical and economic outcomes of population-wide FH genomic screening versus no genomic screening.

Methods

We developed a decision tree plus 10-state Markov model evaluating the identification of patients with an FH variant, statin treatment status, LDL-C levels, MI, and stroke to compare the costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness of population-wide FH genomic screening. FH variant prevalence (0.4%) was estimated from the Geisinger MyCode Community Health Initiative (MyCode). Genomic test costs were assumed to be $200. Age and sex-based estimates of MI,

SUBMITTER: Spencer SJ 

PROVIDER: S-EPMC9926472 | biostudies-literature | 2022 Sep-Oct

REPOSITORIES: biostudies-literature